Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer

WATERTOWN, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the appointment of Kaya Pai Panandiker as chief commercial officer and a member of Neumora’s executive team, reporting to Henry Gosebruch, president and chief executive officer. Ms. Pai Panandiker has more than 20 years of experience commercializing medicines in areas of significant unmet need, including the commercial launches of TRINTELLIX^® (vortioxetine) and REXULTI^® (brexpiprazole) for major depressive disorder (MDD) and schizophrenia.

“I am excited to welcome Kaya to Neumora. As we progress toward the potential commercialization of navacaprant and further advance our pipeline, her extensive commercial expertise in neuropsychiatry will be invaluable,” said Henry Gosebruch, president and chief executive officer, Neumora.

Ms. Pai Panandiker brings extensive commercial strategy and execution expertise to Neumora, having led the launches of multiple neuropsychiatry products throughout her career. Prior to joining Neumora, Ms. Pai Panandiker served as head of commercial at Cerevel Therapeutics and general manager, neuroscience at Lundbeck US. During her time at Lundbeck, Ms. Pai Panandiker led commercialization efforts for its neuroscience franchise, achieving blockbuster sales.

“It is an incredibly exciting time to join Neumora as we progress pivotal studies in MDD and advance a deep pipeline in schizophrenia, Alzheimer’s, Parkinson’s and other disease areas with significant unmet medical need,” said Kaya Pai Panandiker, chief commercial officer, Neumora. “I am impressed with Neumora’s progress to date and look forward to leading a commercial team with the potential to transform the standard of care for millions of patients living with brain diseases.”

Ms. Pai Panandiker holds a master’s in public policy from University of Chicago and a bachelor's in American studies from University of Wisconsin Madison.

About Neumora
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our therapeutic pipeline currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Our work is supported by an integrated suite of translational, clinical and computational tools to generate insights that can enable precision medicine approaches. Our mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about Neumora Therapeutics, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including statements related to: Neumora’s intention to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases; the timing, progress and plans for its therapeutic development programs, including the timing of initiation and data read outs for its programs and studies, as well as its clinical trial and development plans; and other statements identified by words such as “could,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “will,” “would,” or similar expressions and the negatives of those terms. Other than statements of historical facts, all statements contained in this press release, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties that could cause the actual results or to be materially different from the information expressed or implied by these forward-looking statements, including, among others: the risks related to the inherent uncertainty of clinical drug development and unpredictability and lengthy process for obtaining regulatory approvals; risks related to the timely initiation and enrollment in our clinical trials; risks related to our reliance on third parties, including CROs; risks related to serious or undesirable side effects of our therapeutic candidates; risks related to our ability to utilize and protect our intellectual property rights; and other matters that could affect sufficiency of capital resources to fund operations. For a detailed discussion of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Neumora’s business in general, please refer to the risk factors identified in the Company’s filings with the Securities and Exchange Commission (SEC), including but not limited to its Registration Statement on Form S-1, as amended (File No. 333-274229), filed with the SEC on September 11, 2023, and related Prospectus dated September 14, 2023 filed under 424(b)(4) of the Securities Act of 1933, as amended. Forward-looking statements speak only as of the date hereof, and, except as required by law, Neumora undertakes no obligation to update or revise these forward-looking statements.

Neumora Contact:
Helen Rubinstein
315-382-3979
Helen.Rubinstein@neumoratx.com